Streetbeat News

MDRX

Veradigm Inc

https://www.allscripts.com/

CEO

Paul Black

Employees

6,445

Industry

Computer Systems Design Services

allscripts (nasdaq: mdrx) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. our innovative solutions connect people, places and data across an open, connected community of health™. connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. to learn more, visit www.allscripts.com, twitter, youtube and blog.allscripts.com.

Open

10.57

Mkt cap

1.1B

Volume

334K

High

10.74

P/E Ratio

10.69

52-wk high

12.66

Low

10.25

Div yield

N/A

52-wk low

5.01

RBC Capital analyst Sean Dodge has maintained an Outperform rating on Veradigm (NASDAQ:MDRX) but has cut the price target from $22 to $11.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:06 pm

WD-40 Company (NASDAQ:WDFC) shares surged over 17% after reporting Q1 earnings of $1.28 per share, surpassing estimates of $1.05 per share, and sales of $140.42 million, above the expected $134.37 million. Other stocks experienced significant movements in Wednesday's mid-day session, with various companies reporting funding, FDA interactions, earnings, and other corporate updates.

Portfolio Pulse from Avi Kapoor

January 10, 2024 | 6:06 pm

Veradigm, a healthcare information technology solutions unit, has provided its fiscal year 2023 non-GAAP earnings per share (EPS) guidance to be in the range of $0.79 to $0.88.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:15 pm

Veradigm, a healthcare information technology solutions provider, has projected its revenue for the fiscal year 2023 to be between $608 million and $622 million.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:14 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. Exicure (XCUR) saw a 29.8% increase, while Telesis Bio (TBIO) rose by 21.88%. Jin Medical International (ZJYL) increased by 21.33%, Estrella Immunopharma (ESLA) by 15.78%, Amarin Corp (AMRN) by 15.35%, and Bio-Path Hldgs (BPTH) by 12.99%. Conversely, Aclaris Therapeutics (ACRS) fell by 14.1%, Forian (FORA) by 9.93%, Veradigm (MDRX) by 9.86%, cbdMD (YCBD) by 8.87%, ThermoGenesis Holdings (THMO) by 8.58%, and Qilian Intl Hldg Gr (QLI) by 8.32%.

Portfolio Pulse from Benzinga Insights

January 10, 2024 | 1:05 pm

Barclays analyst Stephanie Davis has initiated coverage on Veradigm (NASDAQ:MDRX) with an Equal-Weight rating and set a price target of $11 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 10:32 am

Veradigm, a healthcare data and technology solutions provider, has announced the acquisition of Koha Health, a company specializing in revenue cycle services for the ambulatory healthcare market. The financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 9:06 pm

Veradigm Inc. (MDRX) has been granted continued listing on the Nasdaq Capital Market by the Nasdaq Hearings Panel, conditional upon the company demonstrating compliance with Nasdaq Listing Rule 5250(c)(1) by February 27, 2024. Veradigm is currently noncompliant due to not filing its Annual Report for 2022 and Quarterly Reports for 2023. The company's stock remains listed on the Nasdaq Global Select Market and Veradigm intends to file the overdue reports as soon as possible.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 9:11 pm

Comtech Telecommunications Corp. (CMTL) shares dropped over 16% due to weaker-than-expected quarterly earnings, reporting adjusted earnings of 24 cents per share against estimates of 26 cents. Sales were nearly in line with expectations at $151.91 million versus $151.87 million forecasted. The stock fell to $10.45. Other stocks moved in the session, with notable gainers including Intensity Therapeutics (INTS), MBIA Inc. (MBI), and ALX Oncology Holdings (ALXO), among others. Losers included Cyngn Inc. (CYN), African Agriculture Holdings (AAGR), and Golden Heaven Group Holdings (GDHG).

Portfolio Pulse from Avi Kapoor

December 08, 2023 | 5:58 pm

During Friday's intraday session, several healthcare stocks experienced significant movements. Intensity Therapeutics (INTS) saw a notable increase of 107.2%, while Conduit Pharmaceuticals (CDT) and ALX Oncology Holdings (ALXO) also saw substantial gains. On the other hand, AquaBounty Techs (AQB), Veradigm (MDRX), and Cano Health (CANO) were among the stocks that declined. These movements reflect the dynamic nature of the healthcare sector and may be influenced by company-specific news or broader market trends.

Portfolio Pulse from Benzinga Insights

December 08, 2023 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.